PPARG and fatty liver disease: This suggests that the prolonged accumulation of BBR and its metabolites due to impaired hepatic metabolism in hepatic steatosis results in sustained activation of PPARγ, thereby amplifying the PPARγ agonistic activity of administered BBR.